Angiotensin II-induced venoconstriction involves both AT1 and AT2 receptors and is counterbalanced by nitric oxide

The venoconstrictor effect of Angiotensin II (Ang II) was investigated in the rat mesenteric venules and portal vein. Mesenteric venules were perfused at a constant rate and reactivity to Ang II (0.1 nmol) was evaluated as changes in the perfusion pressure. Rings of portal vein were mounted in organ baths and curves to Ang II (0.1-100 nmol/L) were generated. In venules, Ang II-contraction (10.6 ± 1.1 mmHg) was abolished by losartan (0.9 ± 0.3 mmHg*), reduced by PD 123,319 (5.8 ± 0.9 mmHg*), increased by l-NAME (16.5 ± 1.8 mmHg*) and not altered by indomethacin. In portal veins, curves to Ang II (−log EC50: 8.9 ± 0.1 mol/L) were shifted to the right by losartan (−log EC50: 7.5 ± 0.1 mol/L*) and by PD 123,319 (−log EC50: 8.0 ± 0.1 mol/L*). l-NAME increased the maximal response to Ang II (Emax: 0.91 ± 0.1 g versus 1.62 ± 0.3 g*) and indomethacin had no effect. In conclusion, Ang II induces venoconstriction by activating AT1 and AT2 receptors. Data obtained with l-NAME provide evidence that the basal nitric oxide release from the endothelium of the venous system can modulate the Ang II-induced venoconstriction.